Key result
Only 56% of NSTE-ACS patients receive guideline-recommended quadruple therapy at hospital discharge.
Why the study?
Medical management of ACS remains suboptimal worldwide, prompting this evaluation of medication patterns, trends, and predictors of guideline adherence for NSTE-ACS in the Middle East.
What is the rate of compliance with guideline-recommended quadruple evidence-based medication at discharge in patients with NSTE-ACS in the Middle East?
Observational (n=2,782)
Yes
What is the rate of compliance with guideline-recommended quadruple evidence-based medication at discharge in patients with NSTE-ACS in the Middle East?
Nearly half of NSTE-ACS patients in the Middle East do not receive guideline-directed quadruple medical therapy at discharge, highlighting a significant gap in secondary prevention.
Background: Evaluation of management practices and adherence to treatment guidelines are essential components of improved health-care delivery. Despite the improvement in the implementation of guidelines, the medical management of acute coronary syndrome (ACS) remains suboptimal worldwide. The aim of the present study was to determine medication use patterns, recent trends, and prescription predictors of adherence to guideline-based therapies for non-ST-elevation ACS (NSTE-ACS) in the Middle East. Methods: We evaluated the use of a quadruple evidence-based medication (EBM) combination consisting of the concurrent use of dual antiplatelet therapy, β-blockers, and lipid-lowering agents at discharge among patients ( n = 2782) with NSTE-ACS in four Middle Eastern countries. Results: A total of 56% ( n = 1626) of the patients received all four guideline-recommended medications at hospital discharge. An adjusted model demonstrated that male sex, diabetes, dyslipidemia, prior percutaneous coronary intervention, prior myocardial infarction, prior coronary artery bypass graft, admission to a catheterization-equipped hospital, and smoking were positively correlated with EBM prescription on discharge. Conversely, cardiogenic shock, heart failure, renal impairment, higher GRACE risk score, and bleeding negatively correlated with concurrent use of the quadruple EBM combination. Conclusion: Nearly half of NSTE-ACS patients in the Middle East do not receive the quadruple EBM combination. Efforts are needed to bridge this gap between practice and guidelines.
No takes yet. Share an insight, caveat, or question.
Alajmi et al. (2021) conducted an observational in Non-ST-elevation acute coronary syndromes (NSTE-ACS) (n=2,782). Quadruple evidence-based medication (EBM) combination was evaluated on Use of a quadruple evidence-based medication (EBM) combination at discharge. Only 56% of patients with NSTE-ACS received the guideline-recommended quadruple evidence-based medication combination at hospital discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: